
Opinion|Videos|January 24, 2024
REACH3: Ruxolitinib in Steroid Refractory cGvHD
Author(s)Robert Zeiser, MD, Nelson J. Chao, MD
Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















